Empowering Tomorrow’s Health: Redefining Lives Through Gene Therapy Innovation
NGGT Inc. was established in March 2020 to develop gene therapies to treat retinal, metabolic, and neurodegenerative diseases. Our team is composed of industry leaders with extensive experience in AAV gene therapy and is powered by its global talent base of over 100 employees at our San Francisco, US and Suzhou, China sites. Our collaborative efforts with academics and leading pharma companies, plus our 90,000 square foot cutting-edge cGMP facility with seamless quality control and integrated operations allows NGGT to rapidly develop new solutions and enhance product quality and efficiency.
Our Mission
At NGGT Inc., we are dedicated to developing innovative gene therapies to treat genetic rare diseases such as Bietti’s Crystalline Dystrophy (BCD) and Phenylketonuria (PKU). Our cutting-edge dual-functional vector technology enables us to create therapies that address the root causes of these conditions. Beyond rare diseases, our gene therapy solutions have the potential to treat a variety of other illnesses with clear pathological mechanisms, offering long-term treatment alternatives for conditions like wet age-related macular degeneration (wetAMD), diabetes, and neurodegenerative diseases.
Our Vision
With our extensive experience and pioneering technology, we aim to bring new treatments to patients with unmet medical needs, significantly improving their quality of life. Our commitment to innovation and excellence drives us to make a meaningful impact in the field of gene therapy.